1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents

Iain Robert Greig (Inventor), Ruth Alexandra Ross (Inventor), Roger Guy Pertwee (Inventor)

Research output: Patent

Abstract

The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain 1,5-di-aryl-pyrazole compounds. The present invention also pertains to the use of such compounds in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor, for example: an eating disorder; obesity; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget's disease of bone; bone related cancer; a disease or disorder with an inflammatory or autoimmune component; rheumatoid arthritis; inflammatory bowel disease; psoriasis; a psychiatric disease or disorder; anxiety; mania; schizophrenia; a disease or disorder characterised by impairment of memory and/or loss of cognitive function; memory impairment; loss of cognitive function; Parkinson's disease; Alzheimer's disease; dementia; a cardiovascular disease or disorder; congestive heart failure; cardiac hypertrophy; and myocardial infarction.
Original languageEnglish
Patent numberWO2008/099139
IPCA61K31/415; A61P29/00; C07D231/12;
Publication statusPublished - 21 Aug 2008

Fingerprint

Pyrazoles
Cannabinoid Receptor Antagonists
Cognition
Smoking
Osteitis Deformans
Therapeutics
Bone Neoplasms
Cannabinoids
Bone Diseases
Memory Disorders
Cardiomegaly
Smoking Cessation
Bipolar Disorder
Inflammatory Bowel Diseases
Psoriasis
Osteoporosis
Substance-Related Disorders
Parkinson Disease
Psychiatry
Dementia

Cite this

Greig, I. R., Ross, R. A., & Pertwee, R. G. (2008). IPC No. A61K31/415; A61P29/00; C07D231/12; . 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents. (Patent No. WO2008/099139).

1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents. / Greig, Iain Robert (Inventor); Ross, Ruth Alexandra (Inventor); Pertwee, Roger Guy (Inventor).

IPC No.: A61K31/415; A61P29/00; C07D231/12; . Patent No.: WO2008/099139.

Research output: Patent

Greig, IR, Ross, RA & Pertwee, RG 2008, 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents, Patent No. WO2008/099139, IPC No. A61K31/415; A61P29/00; C07D231/12; .
Greig, Iain Robert (Inventor) ; Ross, Ruth Alexandra (Inventor) ; Pertwee, Roger Guy (Inventor). / 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents. IPC No.: A61K31/415; A61P29/00; C07D231/12; . Patent No.: WO2008/099139.
@misc{1ab42c3b3b0e46b6a0f8a95ea596fe4e,
title = "1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents",
abstract = "The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain 1,5-di-aryl-pyrazole compounds. The present invention also pertains to the use of such compounds in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor, for example: an eating disorder; obesity; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget's disease of bone; bone related cancer; a disease or disorder with an inflammatory or autoimmune component; rheumatoid arthritis; inflammatory bowel disease; psoriasis; a psychiatric disease or disorder; anxiety; mania; schizophrenia; a disease or disorder characterised by impairment of memory and/or loss of cognitive function; memory impairment; loss of cognitive function; Parkinson's disease; Alzheimer's disease; dementia; a cardiovascular disease or disorder; congestive heart failure; cardiac hypertrophy; and myocardial infarction.",
author = "Greig, {Iain Robert} and Ross, {Ruth Alexandra} and Pertwee, {Roger Guy}",
year = "2008",
month = "8",
day = "21",
language = "English",
type = "Patent",
note = "WO2008/099139; A61K31/415; A61P29/00; C07D231/12;",

}

TY - PAT

T1 - 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents

AU - Greig, Iain Robert

AU - Ross, Ruth Alexandra

AU - Pertwee, Roger Guy

PY - 2008/8/21

Y1 - 2008/8/21

N2 - The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain 1,5-di-aryl-pyrazole compounds. The present invention also pertains to the use of such compounds in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor, for example: an eating disorder; obesity; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget's disease of bone; bone related cancer; a disease or disorder with an inflammatory or autoimmune component; rheumatoid arthritis; inflammatory bowel disease; psoriasis; a psychiatric disease or disorder; anxiety; mania; schizophrenia; a disease or disorder characterised by impairment of memory and/or loss of cognitive function; memory impairment; loss of cognitive function; Parkinson's disease; Alzheimer's disease; dementia; a cardiovascular disease or disorder; congestive heart failure; cardiac hypertrophy; and myocardial infarction.

AB - The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain 1,5-di-aryl-pyrazole compounds. The present invention also pertains to the use of such compounds in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor, for example: an eating disorder; obesity; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget's disease of bone; bone related cancer; a disease or disorder with an inflammatory or autoimmune component; rheumatoid arthritis; inflammatory bowel disease; psoriasis; a psychiatric disease or disorder; anxiety; mania; schizophrenia; a disease or disorder characterised by impairment of memory and/or loss of cognitive function; memory impairment; loss of cognitive function; Parkinson's disease; Alzheimer's disease; dementia; a cardiovascular disease or disorder; congestive heart failure; cardiac hypertrophy; and myocardial infarction.

M3 - Patent

M1 - WO2008/099139

ER -